title: Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
abstract: OBJECTIVE
  We evaluated the short- and long-term effects of flosequinan in 47 patients with severe heart failure despite ongoing captopril treatment.
  
  
  BACKGROUND
  There have been no previous evaluations of the long-term hemodynamic effects of any direct-acting vasodilator in patients with heart failure receiving an angiotensin-converting enzyme inhibitor. Flosequinan is an arterial and venous vasodilator with actions similar to those of the hydralazine-isosorbide dinitrate combination.
  
  
  METHODS
  After baseline hemodynamic measurements using balloon-tipped pulmonary artery and radial arterial catheters, patients were randomized to receive 50, 100 or 150 mg of flosequinan daily. Hemodynamic variables were measured immediately before and after short-term flosequinan administration and after 8 weeks of therapy.
  
  
  RESULTS
  With short-term flosequinan administration, mean arterial, right atrial and left ventricular filling pressures decreased by 6.4 +/- 1.1, 3.8 +/- 0.5 and 7.3 +/- 0.7 mm Hg, respectively (all p < 0.001). Cardiac index increased by 0.5 +/- 0.1 liters/min per m2, systemic vascular resistance decreased by 616 +/- 105 dynes.s.cm-5 and heart rate increased by 4 +/- 1 beats/min (all p < 0.001). After 8 weeks of long-term flosequinan administration, the vasodilator effect of a dose of flosequinan persisted. Compared with pretreatment baseline values, mean arterial, right atrial and left ventricular filling pressures at the peak effect of flosequinan were decreased by 3.5 +/- 1.3, 2.8 +/- 0.7 and 5.1 +/- 1.3 mm Hg, respectively (all p < 0.01). Systemic vascular resistance had decreased by 585 +/- 95 dynes.s.cm-5, cardiac index had increased by 0.5 +/- 0.1 liters/min per m2 and heart rate had increased by 10 +/- 2 beats/min (all p < 0.001).
  
  
  CONCLUSIONS
  The arterial and venous vasodilator flosequinan exerts both short- and long-term sustained hemodynamic effects in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
authors.affiliation: Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.
authors.forename: S S
authors.initials: SS
authors.lastname: Gottlieb
authors.forename: M L
authors.initials: ML
authors.lastname: Kukin
authors.forename: J
authors.initials: J
authors.lastname: Penn
authors.forename: M L
authors.initials: ML
authors.lastname: Fisher
authors.forename: M
authors.initials: M
authors.lastname: Cines
authors.forename: N
authors.initials: N
authors.lastname: Medina
authors.forename: M
authors.initials: M
authors.lastname: Yushak
authors.forename: M
authors.initials: M
authors.lastname: Taylor
authors.forename: M
authors.initials: M
authors.lastname: Packer
mesh_terms: D000328:Adult; D000368:Aged; D002216:Captopril / Q000627:therapeutic use*; D002407:Catheterization, Swan-Ganz; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013815:Thermodilution; D013997:Time Factors; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016277:Ventricular Function, Left
chemical_list: D004071:Digitalis Glycosides; D004232:Diuretics; D011804:Quinolines; D014665:Vasodilator Agents; C047316:flosequinan; D002216:Captopril